What are the most common imaging findings in clear cell renal cell carcinoma?
Best insight from top research papers
Clear cell renal cell carcinoma (ccRCC) exhibits two common imaging patterns: solid and cystic. Solid ccRCC tumors are heterogeneous with minor cystic changes and rarely exhibit calcifications. They show hyperintensity on T2-weighted images compared to renal cortex and maximal enhancement on corticomedullary phase with a delayed washout. On the other hand, cystic ccRCC tumors are classified as Bosniak IV, III, or IIF, with a predominant unilocular pattern. These tumors enhance gradually during the corticomedullary and nephrogenic phases. The imaging characteristics of solid ccRCC are distinct from papillary RCC and similar to clear cell papillary RCC.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The provided paper does not mention the most common imaging findings in clear cell renal cell carcinoma. | |
| The most common imaging findings in clear cell papillary renal cell carcinoma are heterogeneous tumors with minor cystic changes and hyperintensity on T2-weighted images. | |
| The paper does not provide information about the most common imaging findings in clear cell renal cell carcinoma. | |
6 Citations | The paper does not provide information on the most common imaging findings in clear cell renal cell carcinoma. |
| The paper does not provide information about the most common imaging findings in clear cell renal cell carcinoma. |
Related Questions
What is a clear cell renal cell cancer?6 answersClear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer, characterized by its origin in the proximal tubular epithelial cells and its aggressive behavior. It accounts for 75-90% of all kidney tumors, making it a significant concern in the field of oncology. The disease is notorious for its ability to metastasize, recur, and resist traditional cancer treatments such as radiotherapy and chemotherapy, posing a substantial burden on human health due to its refractory nature and increasing incidence rate.
Molecularly, ccRCC is distinguished by specific genetic and epigenetic alterations, including the loss of chromosome 3p and inactivation of the von Hippel–Lindau (VHL) gene, which are common in most cases. Additional driver mutations such as SETD2, PBRM1, and BAP1 contribute to genomic instability and tumor cell metastasis. The disease's peculiarities, such as erythrocytosis due to erythropoietin overproduction and a combination of early metastases with sometimes apparent dormancy and late recurrence, suggest a complex pathogenesis.
Recent studies have focused on understanding the genomic profile, epidemiological characteristics, and overall survival of ccRCC patients, identifying mutations in genes like SDHD and ARID1A as associated with poor prognosis. Despite advancements in immunotherapy, a sustained clinical response is achieved in only a minority of patients, indicating a need for further research into the mechanisms of malignant transition and resistance to therapy.
Given its prevalence and the challenges in treatment, ccRCC has been a subject of extensive research aiming to improve diagnostic, prognostic, and therapeutic strategies. This includes exploring the clinical and pathological features, diagnostic criteria, and differential diagnosis to better understand and manage the disease. The goal is to integrate molecular profiles of tumors into clinical practice, potentially through precision medicine and machine learning, to enhance the diagnosis and treatment of ccRCC.
What is the relationship between ECHO findings and clinical outcomes in patients with chronic kidney disease?4 answersEchocardiographic findings in patients with chronic kidney disease (CKD) have been found to be associated with clinical outcomes. Left ventricular abnormalities, including left ventricular hypertrophy (LVH), systolic dysfunction, diastolic dysfunction, and valvular calcification, are common in CKD patients and may contribute to worse clinical outcomes. In patients with CKD and heart failure (HF), different subtypes of HF, such as HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF), have been shown to have varying impacts on long-term outcomes and renal function, with HFrEF being associated with the greatest risks. Additionally, musculoskeletal ultrasonographic changes related to hyperuricemia have been observed in CKD patients, leading to chronic musculoskeletal pain and decreased quality of life. Overall, echocardiographic findings in CKD patients can provide valuable information about cardiac structure and function, which may have implications for clinical outcomes and quality of life.
What is the role of the kidney biopsy in cancer patients?5 answersKidney biopsy plays a critical role in the management of kidney toxicities in cancer patients treated with novel cancer agents. It provides valuable diagnostic information and helps guide treatment decisions. The histological evaluation of kidney disorders induced by targeted/immunotherapy is limited, and kidney biopsy allows for a more accurate diagnosis. The most common histological findings in cancer patients undergoing kidney biopsy include tubular interstitial nephritis, acute tubular necrosis, and thrombotic microangiopathy. The information obtained from kidney biopsy can lead to appropriate treatment, such as the use of steroids or rituximab, and can help achieve renal response. Additionally, kidney biopsy can identify the underlying kidney disease and guide the cancer treatment plan. Overall, kidney biopsy is strongly encouraged for cancer patients showing adverse kidney effects of novel cancer agents.
What are the most common imaging techniques used in cancer diagnosis?4 answersThe most common imaging techniques used in cancer diagnosis include mammography, digital breast tomosynthesis, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and fluorodeoxyglucose-positron emission tomography (FDG-PET). Mammography is the primary screening tool for breast cancer detection, while ultrasound and MRI are also used in breast imaging. CT and PET are widely employed for the screening and identification of various pathologies, including lung cancer. FDG-PET is particularly valuable in cancers of the lung, breast, prostate, lymphoma, and more. These imaging techniques provide information about the morphology, structure, metabolism, and functions of cancer cells, aiding in diagnosis, staging, target definition, and response assessment of cancer. The development of novel nanotechnology-based probes has further improved the quality of cancer research and diagnosis.
What is the recent research on kidney tumours?5 answersRecent research on kidney tumors has focused on various aspects of these malignancies. Studies have explored the role of microRNAs (miRNAs) in renal cell carcinoma (RCC), with more than 82 miRNAs identified as being involved in renal cancers. The use of exosomes as mediators of intercellular communication in the tumor microenvironment has also been investigated, with potential applications for the diagnosis and treatment of kidney cancer. Additionally, a retrospective analysis of patients who underwent surgical removal of clear cell carcinoma found morpho-functional changes in the kidneys depending on tumor size and the presence of systemic diseases. The incidence of new cases of renal cell carcinoma has been increasing, and the role of trans-arterial embolization (TAE) in the treatment of these tumors has been explored, although the evidence for its effectiveness is inconclusive. Furthermore, the new WHO classification of renal tumors has improved the understanding and accurate diagnosis of these neoplasms.
What is the common inconclusive findings disease in MRI of knee that needs ct?5 answersThe common inconclusive finding in MRI of the knee that may require further evaluation with CT is bone contusions.